Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults

Vaccine

Volumn 33, Issue 36, 2015, Pages 4647-4652

  Song, Joon Young ^a   Cheong, Hee Jin ^a   Tsai, T F ^b,d   Chang, Hyun ah ^c   Choi, Min Joo ^a   Jeon, Ji Ho ^a   Kang, Seong Hee ^a   Jeong, Eun Ju ^a   Noh, Ji Yun ^a   Kim, Woo Joo ^a  

^a Korea University College of Medicine   (South Korea)

^b City of Cambridge   (United States)

^c Novartis Korea Ltd   (South Korea)

^d Takeda Vaccines Inc   (United States)

Author keywords

Emulsion adjuvant; Influenza vaccine; Pneumococcal polysaccharide vaccine

Indexed keywords

INFLUENZA VACCINE; MIFAMURTIDE; OPSONIN; PNEUMOCOCCUS VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; BACTERIUM ANTIBODY; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; MF59 OIL EMULSION; POLYSORBATE; SQUALENE; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; ASSAY; CHILL; CONTROLLED STUDY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VIRUS A H3N2; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MULTIPLEX OPSONOPHAGOCYTIC KILLING ASSAY; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; VACCINATION; VIRUS STRAIN; BLOOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HEMAGGLUTINATION INHIBITION TEST; IMMUNIZATION; PATHOLOGY; SERUM BACTERICIDAL ANTIBODY ASSAY; TREATMENT OUTCOME; VERY ELDERLY;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION SCHEDULE; INFLUENZA VACCINES; MALE; OPSONIN PROTEINS; PNEUMOCOCCAL VACCINES; POLYSORBATES; SERUM BACTERICIDAL ANTIBODY ASSAY; SQUALENE; TREATMENT OUTCOME; VACCINES, INACTIVATED;

EID: 84939495272     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.05.003     Document Type: Article

References (25)

1. Song J.Y., Cheong H.J., Heo J.Y., Noh J.Y., Seo Y.B., Kim I.S., et al. Outpatient-based pneumococcal vaccine campaign and survey of perceptions about pneumococcal vaccination in patients and doctors. Yonsei Med J 2013, 54:469-475.
2. Frenck R.W., Gurtman A., Rubino J., Smith W., van Cleeff M., Jayawardene D., et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol 2012, 19:1296-1303.
3. Schwarz T.F., Flamaing J., Rümke H.C., Penzes J., Juergens C., Wenz A., et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine 2011, 29:5195-5202.
4. Schwarz T.F., Schmoele-Thoma B. Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged ≥65 years. Vaccine 2013, 31:291-294.
5. DeStefano F., Goodman R.A., Noble G.R., McClary G.D., Smith S.J., Broome C.V. Simultaneous administration of influenza pneumococcal vaccines. J Am Med Assoc 1982, 247:2551-2554.
6. Del Giudice G., Rappuoli R. Inactivated and adjuvanted influenza vaccines. Curr Top Microbiol Immunol 2015, 386:151-180.
7. Frey S.E., Reyes M.R., Reynales H., Bermal N.N., Nicolay U., Narasimhan V., et al. Comparison of the safety and immunogenicity of an MF59(R)-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 2014, 32:5027-5034.
8. Mannino S., Villa M., Apolone G., Weiss N.S., Groth N., Aquino I., et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 2012, 176:527-533.
9. Seo Y.B., Choi W.S., Lee J., Song J.Y., Cheong H.J., Kim W.J. Comparison of the immunogenicity and safety of the conventional subunit MF59-adjuvanted, and intradermal influenza vaccines in the elderly. Clin Vaccine Immunol 2014, 21:989-996.
10. Spadea A., Unim B., Colamesta V., Meneghini A., D'Amici A.M., Giudiceandrea B., et al. Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study. Vaccine 2014, 32:5290-5294.
11. Calabro S., Tritto E., Pezzotti A., Taccone M., Muzzi A., Bertholet S., et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 2013, 31:3363-3369.
12. O'Hagan D.T., Ott G.S., De Gregorio E., Seubert A. The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 2012, 30:4341-4348.
13. Cox N.J., Ziegler T. Influenza viruses. Manual of clinical microbiology 2003, 1360-1365. ASM Press, Washington, DC. 8th ed. P.R. Murray, E.J. Barron, J.H. Jorgensen, M.A. Pfaller, R.H. Yolken (Eds.).
14. European Committee for Proprietary Medicinal Products Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96) 1997, The Europen Agency for the Evaluation of Medicinal Products, London, UK.
15. Burton R.L., Nahm M.H. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol 2006, 13:1004-1009.
16. Kim K.H., Yu J., Nahm M.H. Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies. Clin Diagn Lab Immunol 2003, 10:616-621.
17. Romero-Steiner S., Frasch C.E., Carlone G., Fleck R.A., Goldblatt D., Nahm M.H. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 2006, 13:165-169.
18. Wang D., Burton R.L., Nahm M.H., Soong S.J. A four-parameter logistic model for estimating titers of functional multiplexed pneumococcal opsonophagocytic killing assay. J Biopharm Stat 2008, 18:307-325.
19. U.S.Department of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials 2007.
20. Walter N.D., Taylor T.H., Shay D.K., Thompson W.W., Brammer L., Dowell S.F., et al. Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis Off Publ Infect Dis Soc Am 2010, 50:175-183.
21. Kee S.Y., Lee J.S., Cheong H.J., Chun B.C., Song J.Y., Choi W.S., et al. Influenza vaccine coverage rates and perceptions on vaccination in South Korea. J Infect 2007, 55:273-281.
22. Fedson D.S., Nicolas-Spony L., Klemets P., van der Linden M., Marques A., Salleras L., et al. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines 2011, 10:1143-1167.
23. Gilchrist S.A., Nanni A., Levine O. Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine: an approach for policymakers. Am J Public Health 2012, 102:596-605.
24. Tomczyk S., Bennett N.M., Stoecker C., Gierke R., Moore M.R., Whitney C.G., et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkl Rep 2014, 63:822-825.
25. Sanford M. Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed): in older adults. Drugs 2012, 72:1243-1255.